Gilead Sciences (NASDAQ:GILD) CFO Andrew Dickinson Sells 3,000 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the sale, the chief financial officer directly owned 153,503 shares in the company, valued at $18,727,366. This represents a 1.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Gilead Sciences Stock Down 0.8%

Shares of GILD traded down $1.00 during midday trading on Tuesday, hitting $118.78. The stock had a trading volume of 6,211,164 shares, compared to its average volume of 7,887,689. The firm has a market cap of $147.37 billion, a price-to-earnings ratio of 18.42, a price-to-earnings-growth ratio of 0.67 and a beta of 0.32. The company has a 50 day simple moving average of $122.02 and a two-hundred day simple moving average of $115.87. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the firm earned $2.02 earnings per share. Gilead Sciences’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Institutional Investors Weigh In On Gilead Sciences

Hedge funds have recently bought and sold shares of the company. Mirabella Financial Services LLP grew its holdings in Gilead Sciences by 32.7% during the third quarter. Mirabella Financial Services LLP now owns 5,807 shares of the biopharmaceutical company’s stock worth $643,000 after purchasing an additional 1,430 shares during the period. Saranac Partners Ltd acquired a new stake in shares of Gilead Sciences in the third quarter valued at approximately $118,000. Severin Investments LLC bought a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $463,000. Allworth Financial LP boosted its stake in shares of Gilead Sciences by 4.1% during the 3rd quarter. Allworth Financial LP now owns 48,086 shares of the biopharmaceutical company’s stock worth $5,338,000 after acquiring an additional 1,885 shares during the period. Finally, IFP Advisors Inc increased its holdings in shares of Gilead Sciences by 63.0% during the 3rd quarter. IFP Advisors Inc now owns 10,997 shares of the biopharmaceutical company’s stock worth $1,225,000 after acquiring an additional 4,252 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GILD has been the topic of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 price objective on shares of Gilead Sciences in a research report on Friday, October 31st. Sanford C. Bernstein reissued an “outperform” rating on shares of Gilead Sciences in a research report on Monday, November 3rd. Wall Street Zen upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Finally, TD Cowen upped their target price on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $131.54.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.